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Abstract
Background: Obesity is a major health problem. A food field research that has recently aroused considerable
interest is the potential of natural products to counteract obesity. Yerba Mate may be helpful in reducing body
weight and fat. The aim of this study was to investigate the efficacy and safety of Yerba Mate supplementation in
Korean subjects with obesity.
Methods: A randomized, double-blind, placebo-controlled trial was conducted. Subjects with obesity (body mass
index (BMI) ≥ 25 but < 35 kg/m2 and waist-hip ratio (WHR) ≥ 0.90 for men and ≥ 0.85 for women) were given oral
supplements of Yerba Mate capsules (n = 15) or placebos (n = 15) for 12 weeks. Subjects take three capsules per
each meal, total three times in a day (3 g/day). Measured outcomes were efficacy (abdominal fat distribution,
anthropometric parameters and blood lipid profiles) and safety (adverse events, laboratory test results and vital
signs).
Results: During 12 weeks of Yerba Mate supplementation, decreases in body fat mass (P = 0.036) and percent body fat
(P = 0.030) compared to the placebo group were statistically significant. WHR was significantly decreased (P = 0.004) in
the Yerba Mate group compared to the placebo group. No clinically significant changes in any safety parameters were
observed.
Conclusions: Yerba Mate supplementation decreased body fat mass, percent body fat and WHR. Yerba Mate was a
potent anti-obesity reagent that did not produce significant adverse effects. These results suggested that Yerba Mate
supplementation may be effective for treating obese individuals.
Trial registration: ClinicalTrials.gov: (NCT01778257)
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Background
Obesity is a major health problem. Overweight and obes-
ity are defined by the World Health Organization (WHO)
as abnormal or excessive fat accumulation that increases
the risk of type 2 diabetes, cardiovascular disease and sev-
eral types of cancers [1, 2]. Obesity continues to be one of
the biggest global challenges in the 21st century, with at
least 2.8 million adults dying each year from conditions
resulting from being overweight and obeses [3].
Many efforts to overcome obesity have focused on de-
veloping anti-obesity agents. Among drugs, fenfluramine,
dexfenfluramine and sibutramine reduce energy intake,
suppress hunger and enhance satiety [4]. However, only a
few of these drugs enter and stay in the market because
most are associated with serious side effects. Common
side effects include insomnia, dry mouth, constipation,
nausea and headache. In addition, sibutramine is associ-
ated with increased blood pressure and pulse rate, ven-
tricular and supraventricular tachyarrhythmias and angina
pectoris, raising concerns about a potential increase in
cardiac risk [5, 6]. Because of potential adverse side effects,
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anti-obesity drugs are recommended to be prescribed for
obesity only when the benefits of treatment clearly out-
weigh the risks. Whereas drug for antiobesity is effective
but with some concern about side effect, most functional
foods that are generally considered safe have not been sci-
entifically validated for treating obesity or their effects are
not statistically significant [7, 8].
Yerba Mate, the dried leaves of the plant Ilex paraguar-
iensis, is currently consumed by over 1 million people
worldwide, traditionally in many South American coun-
tries including Argentina, Brazil, Uruguay, Paraguay. More
recently, Yerba Mate tea has been consumed in North
America and Europe [9]. Yerba Mate beverages are re-
ported to have biological activities, probably due to their
high polyphenol content. Phenolic compounds have long
been known to possess biological functions. In addition to
polyphenols such as flavonoids (quercetin and rutin) and
phenolic acids (chlorogenic and caffeic acids), Yerba Mate
is also rich in caffeine and saponins [10]. Yerba Mate ex-
tracts are especially rich in chlorogenic acids that might
contribute to hypocholesterolemic [11] and weight loss ef-
fects [12]. Chlorogenic acid inhibits adipogenesis by redu-
cing the expression of genes regulating adipogenesis in
3T3-L1 cells and in mouse model of HFD-induced obesity
[13]. In these regards, it is likely that Yerba Mate may po-
tential alternative for controlling body fat accumulation
and weight. In vitro and in vivo studies have demonstrated
that Yerba Mate modulates signaling pathways, has che-
mopreventive activities [14, 15], enhance intestinal propul-
sion [16], has vasodilatation effects [17], inhibits glycation
[18], inhibits oxidative stress [19] and has inflammatory
effects [20]. Yerba Mate suppresses body weight gain and
visceral fat accumulation and decreases serum levels of
cholesterol, triglycerides, LDL cholesterol [21, 22]. Our
previous study reported that Yerba Mate reduces body
weight in mice with obesity induced by a high-fat diet.
After feeding animals Yerba Mate for 4 weeks, we observed
a decrease in total cholesterol, leptin levels and blood glu-
cose that ultimately led to reduce their body weight [23].
Taking into account that Yerba Mate is especially rich in
chlorogenic acid and several bioactive compounds, it sug-
gest that it is possible to inhibit obesity.
Based on encouraging results from animal studies, we
performed a clinical trial to evaluate the anti-obesity ef-
fects of Yerba Mate on humans. The objective of the
study was to document the effects of 12 weeks of Yerba
Mate supplementation on body fat composition in obese




The current study was conducted under the 12 weeks,
randomized, double-blind, placebo-controlled clinical trial
according to a computer-generated randomization sched-
ule designed to assign subjects to Yerba Mate or placebo
groups. Neither the investigators nor the subjects knew
the randomization code or the results of the blood param-
eter until after statistical analysis was complete. Subjects
attended a screening visit at which inclusion and exclusion
criteria were assessed. Screening visit evaluation, physical
examination and blood parameter screening tests were
conducted for all subjects within 4 weeks of initial screen-
ing. A random number between 1 and 30 was generated
for each participant and enrollees were scheduled for a
first visit and randomly assigned to either the Yerba Mate
(n = 15) or placebo (n = 15) group. Yerba Mate and pla-
cebo capsules were given to subjects every 6 weeks.
During the 12 weeks intervention period, subjects were
asked to continue their usual diet but not other functional
foods or dietary supplements. Computed tomography
(CT) imaging and testing of biochemical parameters were
evaluated before and after the intervention period for both
groups. Every 6 weeks anthropometric measurements,
lipid profile, vital signs and nutrient intake, adverse events,
lifestyle and capsule compliance were evaluated. During
the run-in phase of the trial, all subjects were instructed
to maintain their normal diet and physical activity. A
CONSORT checklist for the reporting of this study can be
found in Additional file 1.
Subjects
From July 2011 through May 2012, subjects were recruited
at the Clinical Trial Center for Functional Foods (CTCF2)
of Chonbuk National University Hospital (Jeonju, Republic
of Korea). A total of 37 volunteers agreed to participate.
Only individuals who were obese (body mass index (BMI)
< 35 and ≥ 25 kg/m2 and waist-hip ratio (WHR) ≥ 0.90 for
men or ≥ 0.85 for women) according to the Asia-Pacific
guidelines and were not diagnosed with any other diseases
were included.
The 30 subjects who met the study criteria (age, 43.2 ±
10.6 years; weight, 71.56 ± 10.14 kg; BMI 27.98 ± 2.68 kg/
m2) were randomly divided into two groups (n = 15 each)
and given either Yerba Mate (3150 mg/day) or a placebo
(3150 mg/day). Exclusion criteria were: (a) significant vari-
ation in weight (more 10 %) in the past 3 months; (b) his-
tory of cardiovascular disease, gastrointestinal disease
(Crohn’s disease), previous surgery (caesum or enterocele
surgery), renal disease or abnormal hepatic function; (c)
participation in another clinical trial within the past
3 months; (d) antipsychotic drug therapy within past the
2 months; (e) pregnancy or breast feeding; (f) history of al-
cohol or substance abuse; or (g) allergies or hypersensitiv-
ity to any of the ingredients in the test products. All
subjects provided written informed consent before the in-
vestigation commenced. Study protocols were approved
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by the Institutional Review Board of Chonbuk National
University Hospital (IRB number: CUH 2011–07–18).
The protocol is registered at www.clinicaltrials.gov
(NCT01778257).
Test supplement
Yerba Mate was a standardized product containing chloro-
genic acid 35 mg/g and was prepared by JEJU TECHNO-
PARK (Jeju, Republic of Korea). Dried Yerba Mate leaves
were collected from Argentina and extracted with water at
100 °C for 2 h. Extracts were filtered and concentrated
under reduced pressure to 20 brix at 40–50 °C, dried at
160–180 °C using a spray dryer. Yerba Mate was adminis-
tered in capsule form (333.38 mg Yerba Mate and 16.6 mg
diluting agents in a 350 mg capsule). Administration was
3 g/day Yerba Mate water extract, the recommended daily
dose from Korea Food & Drug Administration (KFDA) in
our clinical trial. The appearance of the Yerba Mate and
placebo capsules was identical (Additional file 2).
Subjects take three capsules per each meal, total three
times in a day (before breakfast, lunch and dinner). Yerba
Mate and placebo capsule packaging was indistinguishable
and was labeled with the subject number. Subjects were
instructed to bring all remaining supplements to each visit
and were withdrawn if supplement consumption was < 70
% of the recommended dose.
Efficacy outcome measurements
The 30 subjects who met the study criteria were asked
to visit the clinic once every 6 weeks (weeks 0, 6 and 12
of the study period) for four clinical visits including the
initial screening. During each visit, current supplementa-
tion use was reviewed and symptoms or side effects were
recorded. During the screening visit, demographic and
lifestyle information was collected (gender, age, alcohol
consumption and smoking). A medical history was taken
and a urine pregnancy test was conducted.
The following parameters were assessed: abdominal
fat distribution was measured and analyzed using CT
(Somatom Sensation 16 MDCT; Siemens, Forchheim,
Germany) before (0 week) and after the 12 weeks inter-
vention period. Body weight, BMI, body fat mass, per-
cent body fat and lean body mass were measured using
the Inbody 3.0 (Biospace, Seoul, Korea) during each
visit. Blood samples were collected after a minimum
12-h fast during initial screening and at the 6 weeks
and 12 weeks intervention period to obtain lipid pro-
files changes of total cholesterol, triglycerides, high-
density lipoprotein (HDL), low-density lipoprotein
(LDL), and free fatty acids. Blood samples were ana-
lyzed with a Hitachi 7600–110 analyzer (Hitachi High
Technologies, Tokyo, Japan) using standard methods in
the biochemical laboratory of Chonbuk National Uni-
versity Hospital.
Safety and dietary evaluation
Extract safety was assessed by the following procedures:
hematology and laboratory tests were conducted during
screening, 0 week and 12 weeks intervention periods for
white blood cell (WBC), red blood cell (RBC), platelet
counts, hemoglobin, hematocrit, total protein, albumin,
alanine transaminase (ALT), aspartate transaminase
(AST), blood urea nitrogen (BUN) and creatinine levels.
Pulse and blood pressure were measured at every visit
after a 5-min rest using an IntelliVue MP70 (Philips,
Eindhovan, Netherlands). A personal report was also
recorded. Subjects maintained their usual diet and ac-
tivity and all completed a dietary record at each visit
during the intervention period to evaluate energy intake
and diet quality. Dietary intake data were analyzed by
the same dietitian using CAN-pro 3.0 software (The
Korea Nutrition Society, Seoul, Korea).
Statistical analysis
Statistical analyses were performed using SAS software,
version 9.2 (SAS Institute, USA). Data are presented as
mean ± standard deviation (SD). The appropriate sample
size was statistically determined to obtain a power of 80 %
with an alpha of 0.05. This study was planned as a feasibil-
ity study, and the minimum sample size needed to detect.
In order to demonstrate decrease of body fat mass, a sam-
ple size of 12 was required under the assumption that de-
crease of body fat mass is 3 kg with a standard deviation
of 2.6 kg. Assuming a 20 % loss to follow-up, we set the
total sample size at 30. Intention-to-treat (ITT) analysis
included all randomized subjects who received at least
one dose of Yerba Mate or placebo capsule. Efficacy and
safety parameters of the ITT group were analyzed. For sta-
tistics we used a mixed effect model approach for ITT
analysis with missing values [24]. General characteristics
were analyzed by independent t-test or Chi-square tests.
The significance of the differences within or between
groups was tested by repeated measures ANOVA and a
paired t-test of the mean. Chi-square tests were performed
to determine differences in the frequencies of categorized




Among the 37 subjects screened, 7 were excluded due to
anthropometric characteristic or laboratory test result cri-
teria. The remaining 30 fulfilled the inclusion criteria and
were divided equally into Yerba Mate and placebo groups.
Three withdrew consent for personal reasons, one discon-
tinued treatment because of adverse side effects and one
had a protocol violation (inclusion/exclusion criteria viola-
tion). Thus, 25 subjects (13 Yerba Mate and 12 placebo
group members) finished the study (Fig. 1).
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Subject characteristics
General subject characteristics are in Table 1. No signifi-
cant difference was observed in baseline characteristics
such as age, height, weight and BMI between the Yerba
Mate and placebo groups.
Dietary assessment
No significant differences in dietary intake (calorie,
carbohydrate, protein and fat) were observed between
the groups during the intervention period (Additional
file 3).
Fig. 1 CONSORT diagram showing participant flow through the 12 weeks intervention. ITT, intention-to-treat population
Table 1 Demographic characteristics of the study subjects
Yerba Mate (n = 15) Placebo (n = 15) Total (n = 30) P value1)
Age (year) 41.5 ± 11.6 44.9 ± 9.6 43.2 ± 10.6 0.379
Height (cm) 160.93 ± 6.95 158.40 ± 7.59 159.67 ± 7.27 0.349
Weight (kg) 74.50 ± 9.83 68.61 ± 9.89 71.56 ± 10.14 0.113
BMI (kg/m2) 28.65 ± 2.09 27.31 ± 3.10 27.98 ± 2.68 0.174
Sex
Male2) 2 (13.3) 2 (13.3) 4 (13.3)
Female 13 (86.7) 13 (86.7) 26 (86.7) >0.9993)
Drinker
Yes 8 (53.3) 6 (40) 14 (46.7)
No 7 (46.7) 9 (60) 16 (53.3) 0.464
Smoker
Yes 0 (0.0) 2 (13.3) 2 (6.7)
No 15 (100) 13 (86.7) 28 (93.3) 0.483
Values are presented as the mean ± S.D
1) Analyzed by independent t test
2) N (%)
3) Analyzed by chi-square tests
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Body fat composition
Changes in BMI, body fat mass and percent body fat
at 0, 6 and 12 weeks of intervention are in Fig. 2.
The decreased in body fat mass (P = 0.036) and per-
cent body fat (P = 0.030) in the Yerba Mate group
compared to the placebo group was significant.
Abdominal fat
Changes in total abdominal fat, abdominal visceral fat
and abdominal subcutaneous fat before and after the
12 weeks intervention period were analyzed (Table 2).
After 12 weeks, no significant differences were found in
area of total abdominal fat. Areas of abdominal visceral
and subcutaneous fat tended to decrease in the Yerba
Mate group, although no significant differences were ob-
served between the two groups.
Lipid profile changes
Changes in serum level of total cholesterol, triglycerides,
LDL cholesterol, HDL cholesterol and free fatty acids at
0, 6 and 12 weeks of intervention are in Table 3. At
12 weeks, free fatty acids levels tended to decrease and
HDL cholesterol levels tended to increase in the Yerba
Mate group. However, no significant differences were
found between the Yerba Mate and placebo groups.
Anthropometric parameters
Changes in anthropometric parameters (height, weight,
waist circumference, hip circumference, WHR, arm cir-
cumference and thigh circumference) at 0, 6 and
12 weeks of intervention are presented in Table 4. De-
creased WHR (P = 0.005) in the Yerba Mate group com-
pared to the placebo group were significant.
Safety analyses
Results of subjects’ complete blood cell count, liver and
kidney function tests and vital signs were within normal
ranges for both the Yerba Mate and placebo groups
throughout the study. Suggesting that Yerba Mate sup-
plementation did not cause any adverse side effects
(Additional files 4, 5 and 6).
Discussion
Our randomized, placebo-controlled, double-blind clin-
ical trial evaluated the safety and efficacy of Yerba Mate
as a supplement for obese Korean people. After 12 weeks
of supplementation, we observed a significant decreased
in body fat mass and percent body fat. WHR also de-
creased significantly in the Yerba Mate group compared
to the placebo group. Unlike currently prescribed anti-
obesity drugs, subjects did not report any specific ad-
verse events.
Our study showed decreased body fat in subjects taking
a Yerba Mate-only supplement. Despite evidence from
previous research supporting the weight-reducing poten-
tial of Yerba Mate, this is the first controlled trial ascribing
an anti-obesity effect to the ingestion of this herb. Yerba
Mate was previously tested in a supplement with other in-
gredients such as green tea, asparagus, black tea, guarana
and kidney bean extracts [25]. Another clinical trial of
6 weeks of treatment with green mate powder extract
Fig. 2 Effects on body fat composition. a Change in BMI during
the study period. b Change in body fat mass during the study
period. The Yerba Mate group was different when compared to
placebo group (P = 0.036). c Change in percent body fat during
the study period. The Yerba Mate group was different compared
to placebo group (P = 0.030). Values are presented mean ± S.D
for 15 subjects. Analyzed by repeated measures ANOVA and the
P value represents the comparison to the placebo group
(P < 0.05)
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(1200 mg/day) showed significant decreased in body fat
mass and percent body fat [26]. In our clinical trial, sub-
jects who completed 12 weeks of treatment with Yerba
Mate showed decreased WHR, body fat mass, percent
body fat and trends in decreased visceral fat and visceral/
subcutaneous fat. Our previous animal study showing that
adipocyte size decreased in a group given Yerba Mate
[23]. Yerba Mate decreases the differentiation of preadipo-
cytes and reduces accumulation of lipids in adipocytes
[27]. These results indicate that decreasing adipose tissue
growth, body fat mass (kg), percent body fat (%) and obes-
ity of Yerba Mate. The potential thermogenic properties
of significantly increasing resting energy expenditure
(REE) for at least four hours post-ingestion in moderated-
level habitual caffeine consumers [28]. The increase in
REE might have been due to a 340-mg proprietary blend
of caffeine anhydrous, guarana, yerba mate and green tea
extract. Another study evaluated the acute effects of oral
administration of 12 commercially available plant prep-
arations aimed at treating human obesity [29]. Only
treatment with a green mate extract changed the re-
spiratory quotient, indicating a rise in the proportion of
oxidized fat that might have led to decreased body fat.
These results suggest the potential of mate leaves for
treatment of obesity.
In our study, a decrease in free fatty acid was observed
with Yerba Mate, although the difference from the pla-
cebo group was not significant. Mate tea also affects other
aspects of lipid metabolism. I. paraguariensis extract
inhibits atherosclerosis progression in cholesterol-fed
rabbits, although it does not decrease serum cholesterol
[22]. A decrease in serum cholesterol and triacylglycerol
concentrations was observed after ingestion of Yerba Mate
extracts in rats fed a high-cholesterol diet [30]. A previous
animal study showed that total cholesterol decreased in a
group given Yerba Mate [23]. Previous studies assumed
that antioxidants in I. paraguariensis A. St.-Hil extracts in-
hibit LDL oxidation in vitro and in vivo, with a potency
comparable to ascorbic acid [31, 32]. Another clinical trial
observed a decreased in serum concentration of choles-
terol and triacylglycerols [26]. Decreased LDL-cholesterol
was observed in normolipidemia and dyslipidemia [33].
Whether metabolic benefits from weight decrease occur
after long-term treatment with Yerba Mate products re-
mains to be determined.
Yerba Mate leaf extracts contain components such as
chlorogenic acid (monocaffeoylquinic and dicaffeoylqui-
nic acids), hydroxycinnamic acids (caffeic acid, quinic
acid) and numerous triterpenic saponins [34]. Chloro-
genic acid is one of the most abundant polyphenols in
fruits such as plums, apples and cherries and has been
shown to reduce body weight as well as improve lipid
metabolism and levels of obesity-related hormones in
mice [12]. Chlorogenic acid inhibits adipogenesis by re-
ducing the expression of genes regulating adipogenesis
in 3T3-L1 cells and in mouse model of HFD-induced
obesity [13]. The mechanisms of Yerba Mate on fat de-
crease, while not directly known, might be due to effects
of single components, as investigated in previous studies.
The Yerba Mate used in our study contained 35 mg/g
chlorogenic acid. Yerba Mate extracts are especially rich
in chlorogenic acids that might contribute to hypocho-
lesterolemic [11] and weight loss effects [12]. Our previ-
ous animal study showing that adipocyte size decreased
Table 3 Lipid profile changes of the Yerba Mate and placebo groups at 0, 6 and 12 weeks
Yerba Mate (n = 15) Placebo (n = 15) P value1)
0 weeks 6 weeks 12 weeks P value1) 0 weeks 6 weeks 12 weeks P value1)
Total cholesterol (mg/dL) 193.6 ± 24.8 197.9 ± 33.2 204.4 ± 36.0 0.384 176.7 ± 28.8 172.3 ± 33.9 174.0 ± 28.4 0.977 0.722
HDL-cholesterol (mg/dL) 45.4 ± 7.7 48.0 ± 10.3 48.2 ± 10.1 0.424 52.3 ± 12.0 50.4 ± 8.3 48.0 ± 8.3 0.369 0.223
LDL-cholesterol (mg/dL) 120.9 ± 27.5 117.8 ± 28.8 121.7 ± 34.6 0.755 101.7 ± 25.6 97.2 ± 27.5 96.7 ± 30.8 0.944 0.862
Triglyceride (mg/dL) 141.5 ± 79.9 130.6 ± 96.3 154.2 ± 96.6 0.325 123.1 ± 65.8 107.2 ± 53.8 127.5 ± 95.1 0.548 0.969
Free Fatty Acid (μEq/L) 516.6 ± 163.6 412.2 ± 128.8 443.5 ± 169.7 0.234 541.5 ± 337.3 541.5 ± 225.6 575.3 ± 220.1 0.286 0.224
Values are presented as the mean ± S.D
1) Analyzed by repeated measures ANOVA
Table 2 Abdominal fat area of the Yerba Mate and placebo groups measured at 0 and 12 weeks
Yerba Mate (n = 15) Placebo (n = 15) P value2)
0 weeks 12 weeks P value1) 0 weeks 12 weeks P value1)
Visceral fat (cm3) 1106.8 ± 387.5 1001.9 ± 338.4 0.145 947.0 ± 256.8 957.8 ± 353.7 0.695 0.181
Subcutaneous fat (cm3) 3123.5 ± 736.2 3101.2 ± 590.4 0.259 2984.0 ± 1040.7 3103.3 ± 1282.3 0.333 0.899
Visceral subcutaneous ratio 0.4 ± 0.1 0.3 ± 0.1 0.140 0.3 ± 0.1 0.3 ± 0.2 0.861 0.175
Values are presented as the mean ± S.D
1) Analyzed by paired t test
2) Analyzed by repeated measures ANOVA
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in a group given Yerba Mate [23] and decreases the dif-
ferentiation of preadipocytes and reduces accumulation
of lipids in adipocytes [27]. Additionally, Yerba Mate in-
hibits body weight gain and visceral fat accumulation
and decreases serum levels of cholesterol, triglycerides,
LDL cholesterol [21, 22]. In these regards, it is likely that
Yerba Mate may potential alternative for controlling
body fat accumulation and weight.
Our study has a limited ability to draw broad conclusions.
First, there is much controversy concerning whether
smokers are actually thinner than nonsmokers. However,
nicotine may be an appetite suppressant and influence an
individual’s eating habits [35]. Although smokers are in-
cluded in the placebo group of this study, the results were
not affected regardless of inclusion smokers and therefore
further study will be designed to consider this point. Sec-
ond, another study reported that Yerba Mate preparation
might reduce energy intake and increase satiety, while indu-
cing weight loss. A weight loss effect was not demonstrated
definitively, although weight and abdominal fat diminished
more in the Yerba Mate group than in the placebo group.
This result might be due to the low statistical power of our
study because of the limited sample size. Moreover, small
sample size in this study limits the generalization of our re-
sults to other populations with obesity. Our study has an
exploratory clinical trial using standardized Yerba Mate and
this study is insufficient to show the effects of Yerba Mate
when associated with lifestyle modification. Thus, further
research needs to take it into account. Finally, we surveyed
subjects’ dietary intake only during the treatment period by
reviewing dietary records. Therefore, dietary intake and ac-
tivity levels were not accurately controlled or impartially in-
vestigated. According to the European Medicines Agency,
subjects in randomized controlled trials evaluating weight
control should adhere to an appropriate weight-reducing
diet for a specified minimum period of time [36]. Despite
these limitations, the data from our study suggested that
Yerba Mate is a safe and effective anti-obesity agent.
Conclusions
In conclusion, the results of this study revealed that Yerba
Mate was a potent anti-obesity reagent that did not pro-
duce any significant adverse effects.
For full determination of the long-term effects of Yerba
Mate application, a larger sample size is needed. Com-
bined with lifestyle modifications, the effects of Yerba
Mate will become more pronounced.
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Table 4 Anthropometric parameters of the Yerba Mate and placebo groups at 0, 6 and 12 weeks
Yerba Mate (n = 15) Placebo (n = 15) P value1)
0 weeks 6 weeks 12 weeks P value 1) 0 weeks 6 weeks 12 weeks P value1)
Height (cm) 160.9 ± 7.0 160.6 ± 7.1 160.6 ± 7.1 - 158.4 ± 7.6 158.5 ± 8.2 159.3 ± 8.0 - -
Weight (kg) 74.5 ± 9.8 73.5 ± 9.2 73.8 ± 9.0 0.742 68.6 ± 9.9 70.8 ± 10.1 71.4 ± 9.5 0.472 0.387
Waist circumference (cm) 92.9 ± 6.2 90.8 ± 4.9 91.3 ± 5.1 0.170 90.1 ± 7.3 91.1 ± 7.8 91.9 ± 8.0 0.529 0.113
Hip circumference (cm) 100.1 ± 4.4 100.2 ± 4.0 100.9 ± 4.4 0.086 97.8 ± 5.0 98.5 ± 5.1 99.0 ± 5.3 0.971 0.478
Waist-hip ratio 0.93 ± 0.05 0.91 ± 0.04† 0.91 ± 0.04‡ 0.003 0.92 ± 0.04 0.92 ± 0.04 0.93 ± 0.04 0.511 0.005
Arm circumference (cm) 33.4 ± 2.4 33.0 ± 2.3 33.0 ± 2.0 0.394 31.8 ± 2.4 32.3 ± 3.2 32.5 ± 2.6 0.869 0.489
Thigh circumference (cm) 53.8 ± 4.2 53.5 ± 4.5 53.5 ± 4.5 0.900 51.2 ± 3.8 52.0 ± 3.9 52.3 ± 3.9 0.535 0.495
Values are presented as the mean ± S.D
1) Analyzed by repeated measures ANOVA. Statistically significant compared to the placebo group
† 0 vs. 6 weeks: waist-hip ratio, P = 0.004
‡ 0 vs. 12 weeks: waist-hip ratio, P = 0.002
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